Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Completed 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 20NIH 5INDUSTRY 4

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Prostatic Neoplasms 90Breast Neoplasms 87Melanoma 86Multiple Myeloma 69Carcinoma, Non-Small-Cell Lung 63Leukemia, Myeloid, Acute 62Lymphoma 59Brain Neoplasms 57Glioblastoma 55Ovarian Neoplasms 51Neoplasms 51Carcinoma, Renal Cell 49Lymphoma, Non-Hodgkin 47Fallopian Tube Neoplasms 47Leukemia, Lymphocytic, Chronic, B-Cell 45Sarcoma 44Gliosarcoma 43Neoplasm Metastasis 39Lung Neoplasms 36Carcinoma, Hepatocellular 35Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Pancreatic Neoplasms 33Glioma 33Lymphoma, Large B-Cell, Diffuse 32Uterine Cervical Neoplasms 31Hematologic Neoplasms 31Colonic Neoplasms 31Small Cell Lung Carcinoma 29Myelodysplastic Syndromes 28Rhabdomyosarcoma 27

Interventions

Lenalidomide 2Watchful Waiting 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Observation 1Melphalan 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
NIH × Has results × Smoldering Multiple Myeloma × Clear all
NCT00114101 2026-05-29

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

National Cancer Institute (NCI)

Phase 3 Active not recruiting
460 enrolled 11 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

NCT01169337 2026-05-01

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
226 enrolled 16 charts
Plasma cell

Smoldering Multiple Myeloma

NCT01237054 2026-02-06

Imaging in MGUS, SMM and MM

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
31 enrolled 13 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

NCT01248455 2019-11-19

A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 8 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00099047 2016-12-30

Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 7 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡